The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of camelid B7-H3 tri-specific killer engagers on natural killer cells in patients with prostate cancer.
 
Nicholas Zorko
Consulting or Advisory Role - Caris Life Sciences; Telix Pharmaceuticals
 
Madison Shackelford
No Relationships to Disclose
 
Asha Bozicevich
No Relationships to Disclose
 
Joshua Walker
No Relationships to Disclose
 
Peter Hinderlie
No Relationships to Disclose
 
Gwen Phung
No Relationships to Disclose
 
Melissa Khaw
No Relationships to Disclose
 
Jacobi Rugloski
No Relationships to Disclose
 
Amanda Russell
No Relationships to Disclose
 
Yvette Soignier
No Relationships to Disclose
 
Laura Kotz
No Relationships to Disclose
 
Laura Bendzick
No Relationships to Disclose
 
Justin Hwang
Research Funding - Astrin Biosciences
 
Emmanuel S. Antonarakis
Honoraria - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene (Inst); ClinicalMind; Clovis Oncology (Inst); Constellation Pharmaceuticals; Curium Pharma; Dendreon (Inst); EcoR1 Capital; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus; Z-Alpha
Consulting or Advisory Role - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; EcoR1 Capital; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus; Z-Alpha
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Martin Felices
Stock and Other Ownership Interests - GT Biopharma
Research Funding - GT Biopharma
Patents, Royalties, Other Intellectual Property - GT Biopharma
 
Jeffrey S. Miller
Leadership - GT Biopharma
Stock and Other Ownership Interests - GT Biopharma
Consulting or Advisory Role - GT Biopharma
Research Funding - GT Biopharma
Patents, Royalties, Other Intellectual Property - GT Biopharma
Travel, Accommodations, Expenses - GT Biopharma